Phase II study looking at the efficacy, safety and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis. It is hoped in this double-blind study to assess the safety of VAY736 and if it has beneficial effects in people who have idiopathic pulmonary fibrosis. The purpose of this study is to determine if VAY736 will improve Lung function.
A subject, investigator and sponsor blinded randomised placebo-controlled, multicentre study to investigate efficacy, safety and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis.
A diagnosis of IPE confirmed by HRCT and/or Lung biopsy using the ATS/ERS guidelines.
- Therapeutic Area
- Respiratory Medicine
- Type of Study
- Phase II Clinical trial, which is subject, sponsor and investigator blinded.
- Study Status
- Open Recruiting
- Principal Investigator
- Professor Michael Keane